TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Attention Bias Modification Treatment for Anxious Youth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis on Anxiety Disorders Interview Schedule for Diagnostic and Statistical Manual-IV Child and Parent versions of Separation Anxiety Disorder, Social Phobia, Specific Phobia, Obsessive-Compulsive Disorder, or Generalized Anxiety Disorder~* Age 7 to 17~Exclusion Criteria:~* Posttraumatic stress disorder or primary diagnosis of major depressive disorder~* Seizure disorder~* Current treatment with psychotropic medication~* Multiple chronic learning disabilities and/or conduct problems

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Attention Bias Modification (Type: ACTIVE_COMPARATOR): Attention Bias Modification computer task
- Placebo Computer Task (Type: PLACEBO_COMPARATOR): Placebo computer task

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* neonates ≤ 30 days of postnatal age at time of operation~* birthweight \> 2.5 kg~* gestational age at birth ≥ 35 weeks~* Patients requiring cardiac surgery who are expected to remain intubated in the CCIU for \> 48 hours~* informed consent by parent or guardian~* approval by treating critical care staff physician~Exclusion Criteria:~* patients with heterotaxy or pre-existing renal or abdominal pathology (eg. preoperative diagnosis of NEC).~* need for ECMO after repair within the study period (data up to that point will be recorded and analyzed).~* Parent refusal of formula for purposes of study~* Patient on vasopressin or norepinephrine infusion~* Parent or legal guardian refuse consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
- 2 (Type: EXPERIMENTAL): The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Finasteride for Chronic Central Serous Chorioretinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Participant must have chronic Central Serous Chorioretinopathy (CSC) in at least one eye as defined by all of the following criteria. This eye will be referred to as the study eye.~* The presence of subretinal fluid, as determined by optical coherence tomography (OCT), AND~* The subretinal fluid must have been present for at least three months or recurrent in cases of chronic CSC/diffuse retinal pigment epitheliopathy, AND/OR~* The presence of characteristic fluorescein angiographic or autofluorescence features of CSC, such as one or more pinpoint leaks and/or diffuse retinal pigment epitheliopathy noted on fluorescein or descending tract lesions on autofluorescence.~* Participant must have a steady fixation in the study eye.~* Participant must have media clear enough in the foveal or parafoveal area in the study eye for good quality photographs.~* Participant must have visual acuity between 20/25 and 20/400 in the study eye.~EXCLUSION CRITERIA:~* Participant has evidence of choroidal neovascularization (CNV) in the study eye.~* Participant is expected to need ocular surgery in the study eye during the first three months of the study.~* Participant has had photodynamic therapy (PDT) or focal laser treatment in the study eye within three months prior to enrollment or is expected to need PDT or focal laser treatment in the study eye during the first three months of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Finasteride 5 mg (Type: EXPERIMENTAL): Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>= 60 years.~* GDS (Reisberg Gobal Dementia Scale) of 2 to 3.~* Geriatric Depression Scale of Yesavage \>=12.~* History of previous depressive episodes resolved, but the emotional situation 15 months before inclusion, necessarily have to be normal.~Exclusion Criteria:~* Established dementia of any cause, or secondary degenerative dementia of any origin~* Primary diagnosis of cognitive impairment with psychiatric illness (schizophrenia , bipolar disorder, personality disorders ... )~* Dual diagnosis of chronic depression, dysthymia more than 15 months duration, or major depression with psychotic or atypical symptoms~* Neuroimaging with significant chronic vascular involvement~* To take drugs with known side effects on cognition and it is suspected that the neuropsychological deficits.~* Moderate or severe sensory deprivation or functional illiteracy in the neuropsychological study can not be performed~* Neoplastic diseasesContraindication to performing a lumbar puncture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years of age~* Ability to understand and sign informed consent~* Biopsy-proven diagnosis of previous cancer (solid or hematologic disease)~* Participants must be diagnosed with active malignancy, defined as the presence of metastatic disease; or patient undergoing curative treatment during cancer treatment, regardless of the therapeutic modality.~* Confirmed diagnosis of COVID-19 by the presence of a positive PCR test or positive serological test and / or diagnosis presumed by the presence of flu-like symptoms associated to suggestive findings on CT scan.~* ECOG performance status 0 to 2~* Patients must have an assessment of adequate organ function within 28 days prior to enrollment, evidenced by:~  * Hemoglobin ≥ 9.0 g / dL~ * Leukometry\> 2,000 / mm3~ * Absolute neutrophil count ≥ 1,500 / mm3~ * Platelet count ≥ 100,000 / mm3~ * Creatinine clearance ≥ 30 mL / min. Creatinine clearance (CrCl) should be calculated according to the Cockcroft-Gault formula.~ * Total bilirubin \<3 x the upper limit of normal (ULN), except for patients with known Gilbert's syndrome.~ * Aspartate aminotransaminase (AST) \<3.0 x LSN.~ * Alanine aminotransaminase (ALT) \<3.0 x ULN.~Exclusion Criteria:~* Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB).~* Patients who presents with severe conditions at the time of diagnosis requiring ICU admission.~* Prior reaction or intolerance to an ARB or ACE inhibitor.~* Blood pressure less than 110/70 mmHg at presentation~* Potassium greater than 5.0 mEq / L~* Pregnancy or breastfeeding~* Prior reaction to Ivermectin.~* Patient currently enrolled in another research protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A: Placebo (Type: PLACEBO_COMPARATOR): Patients will receive ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days.
- ARM B: Ivermectin plus losartan (Type: EXPERIMENTAL): Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consents.~* Man or woman between 18 and 64 years of age.~* Ulcerative colitis (UC) or indeterminate colitis (IC) diagnosed by routine clinical, radiographic, endoscopic, and pathological criteria.~* Patient will be scheduled for non-emergent proctocolectomy or completion proctectomy with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).~* Clinical assessment of patient after IPAA surgery indicates that patient is suitable for early ileostomy reversal~Exclusion Criteria:~* Age \< 18 or \> 64 years~* Colon or rectal cancer~* Crohn's disease or suspected Crohn's disease~* Prednisone dose \> 20 mg per day (or equivalent other steroid dose) within 4 weeks of scheduled IPAA~* Body mass index (BMI) equal to or greater than 40 kg/m2~* Hemodynamic instability (persistent pulse rate \< 50 or \> 120 bpm, systolic blood pressure \< 90 or \> 160 mm Hg, uncontrolled cardiac arrhythmia, or active vasopressor drug use)~* Organ transplant recipient (e.g. Liver, Kidney, Pancreas)~* Immunosuppression due to chemotherapy drug use or systemic disease.~* Sepsis~* Renal insufficiency (i.e. serum creatinine ? 2 mg/dl or need for dialysis)~* Therapeutic anticoagulation (e.g. venous thromboembolic disease, prosthetic heart valve)~* Blood Hemoglobin \< 8 g/dl~* Serum Albumin \< 2.5 g/dl~* Individualized decision by the surgeon to exclude the patient based on sound surgical judgment~* Pregnant patients and female patients who do not satisfy the standard of care requirements of participating centers for an elective surgical procedure.~* Clinical assessment of patient after IPAA surgery indicates that patient is not suitable for early ileostomy reversal~* Participation in another clinical trial within the last 30 days, or simultaneous participation in another clinical trial~* Well-founded doubt about the patient's cooperation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Early ileostomy closure (Type: EXPERIMENTAL): Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
- Late ileostomy closure (Type: ACTIVE_COMPARATOR): Late ileostomy closure will be performed 8 - 12 weeks after IPAA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provides written informed consent~* Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223 dichloride)~* Able to remain still for duration of the imaging procedure (about one hour)~Exclusion Criteria:~* Metallic implants

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (18F NaF/18F FDG PET/MRI, contrast-enhanced MRI) (Type: EXPERIMENTAL): Patients receive 18F NaF and 18F FDG IV over 30 seconds-1 minute and then undergo PET/MRI and contrast-enhanced MRI after 45-60 minutes. Patients undergo imaging at baseline, after course 3 (12 weeks), and after course 6 (24 weeks) of treatment with Ra-223.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perforated Appendicitis With Delayed Presentation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All children with a delayed diagnosis of perforated appendicitis. Delayed diagnosis will be defined as symptoms for 4 or more days. Duration of symptoms will be defined as the time pain started.~* Confirmed diagnosis of perforated appendicitis. The diagnosis of perforated appendicitis will be based on diagnostic imaging (CT scan or ultrasound), showing an established appendiceal abscess or phlegmon.~* Consent to participate~Exclusion Criteria:~* Uncertainty about the diagnosis.~* The need for laparotomy for another reason.~* Free intraperitoneal air on imaging.~* Perforated appendicitis with diffuse abdominal fluid on imaging associated with a clinical picture of severe sepsis.~* Children with other medical condition that may affect the decision to operate e.g: children with inflammatory bowel disease.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Expectant Management (Type: EXPERIMENTAL): Expectant Management
- Operative management (Type: EXPERIMENTAL): Operative management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female 18 to 55 years of age,~* Has 1 or 2 focal chondral lesions, that require repair, per index knee presenting with moderate to severe knee pain. Each lesion is ≤6 mm in depth and has an area of ≥1 cm2 and ≤10 cm2. Arthroscopic confirmation indicates that the lesions are either a non-OCD lesion between grades I and III (D) or an OCD lesion between grades I and IV(A)~* Prior failed chondral treatment is allowed if the procedure occurred \> 6 months for debridement and lavage or \> 1 year for marrow stimulation techniques.~Exclusion Criteria:~* Have more than 2 chondral lesions on the index knee,~* Bipolar lesions on the index knee,~* Greater than 5 degrees of malalignment,~* Require bilateral surgery~* Have a diagnosis of clinical and/or radiographic disease of the index joint.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Randomized to Microfracture
- 2 (Type: EXPERIMENTAL): Randomized to Device
- 3 (Type: EXPERIMENTAL): Non-randomized with lesion greater than 6cmˆ2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Carbohydrates From Nutritional Beverages in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 33 months - 39 months

- Gender: ALL
- Minimum Age: 33 Months
- Maximum Age: 39 Months
- Healthy Volunteers: t

Study Arms:
- Group 1 - Control A (Type: EXPERIMENTAL): Nutritional beverage containing varying types and levels of carbohydrates
- Group 2 - Experimental A (Type: EXPERIMENTAL): Nutritional Beverage with varying types and levels of carbohydrates

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: How to Collect the Expression of Psychological Suffering of Children Under Two Years?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Families say vulnerable falling M.Heaman selection criteria associated with two significant items of Q-Sort, agreeing to participate in the research project.~* Patient 24 months or less at the time of the first consultation PMI.~* Parents / legal representatives agreeing to participate in the research project.~Non inclusion Criteria:~* Serious genetic and somatic pathologies resulting deficiency, physical pain,~* Non-French speaking families.~* Families whose baby is monitored as part of the network grow together because of their prematurity.~* Minor or major Parents Trust

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- Group Maternal and Child Protection (Type: None): Followed by the doctor and pediatric nurse of the Maternal and Child Protection . A child psychiatric consultation (usual care) can take place during the monitoring of this patient.
- Group Home passages (Type: None): A child psychiatric consultation is scheduled in the month following the inclusion and three home passages between the 2nd and 3rd months of follow up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Recovery in Abdominoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medically cleared to undergo elective surgery (including associated anesthesia) at UW Madison Surgery Center (MSC).~Exclusion Criteria:~* Pregnant or breast-feeding women~* Incarcerated women or men~* Individuals unable to give consent due to another condition such as impaired decision-making capacity.~* Men or women who take opioid pain medications on a regular basis prior to surgery~* Men or women with a history of opioid abuse and/or dependence~* Participants with a history of bleeding disorders precluding safe abdominoplasty~* Participants on anticoagulation therapy who have not held their anticoagulation as recommended by their surgeon or anesthesiologist~* Participants not medically cleared for surgery at Madison Surgery Center. This would include participants with sepsis/bacteremia, significant valvular disorders or heart conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Liposomal Bupivacaine (Type: ACTIVE_COMPARATOR): Participants in this study arm will receive intraoperative injection of Liposomal Bupivacaine mixed with Bupivacaine to the abdominal wall.
- Bupivacaine (Type: OTHER): Participants in this study arm will receive intraoperative injection of bupivacaine without Liposomal bupivacaine to the abdominal wall.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years old~* Affiliated to a social security scheme~* Informed consent~* Patient with an indication of liver biopsy eligible for a biopsy under interventional MRI~Exclusion Criteria:~* Patient with a contraindication for MRI exam~* Patient with a contraindication for performing a biopsy~* Pregnancy~* Exclusion period~* Patient unable to receive and understand information about the study~* Patients under guardianship~* Patients under judicial protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test group: with IFE (Type: EXPERIMENTAL): Patients treated with IFE software
- Test group: without IFE (Type: ACTIVE_COMPARATOR): Patients treated with Numaris 4 software

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues